Sherene Loi, MD

976 posts

Sherene Loi, MD banner
Sherene Loi, MD

Sherene Loi, MD

@LoiSher

Professor, Medical Oncologist #LoiLab @PeterMacCC @UniMelb @NBCFAus, #IBSCGchair @etop_ibcsg, @TILsWorkgroup cofounder; coEditor-in-Chief @esmo_iotech own views

Melbourne, Australia Katılım Ağustos 2011
904 Takip Edilen4.3K Takipçiler
Sherene Loi, MD
Sherene Loi, MD@LoiSher·
🤩 ✅ EU CHMP approval: Cami is beneficial in emerging ESR1 mt resistant disease. Remember also ✴️ 1. Genomic biomarkers will only just get cheaper 💰 2. Oncology already accepts the principle that biochemical or molecular progression occurs prior to clinical PD ie in prostate cancer - why do #breastcancer patients need to show OS benefit? 🥴 3. Precision medicine also provides better health economics 🎓
OncoAlert@OncoAlert

News from industry: SERENA6 Update in #BreastCancer Source : AstraZeneca buff.ly/AG5XMPO EU CHMP has recommended approval of AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations after first-line endocrine therapy. Based on SERENA-6, the regimen reduced risk of disease progression or death by 56%, improving median PFS to 16.0 vs 9.2 months. PFS2 also improved, with overall survival data still maturing. #BreastCancer Ping @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc

English
1
11
31
6K
Sherene Loi, MD
Sherene Loi, MD@LoiSher·
Great to have this recent conversation with @OncoAlert @ElisaAgostinett during the recent #ESMOBREAST26. on HR+/HER2- neg #breastcancer and the rapidly changing treatment landscape 👏 #bcsm
OncoAlert@OncoAlert

OncoAlert Horizons | Focus: Breast Cancer Educational Series 🚨 In this session, we explore: Therapeutic options after CDK4/6 inhibitor + endocrine therapy in HR+, HER2– advanced/metastatic breast cancer, and the emerging role of SERD-based combination strategies in this setting. 👩‍⚕️ Faculty: Dr. Sherene Loi @LoiSher Peter MacCallum Cancer Centre, Australia 🇦🇺 Dr. Elisa Agostinetto @ElisaAgostinett Institut Jules Bordet, Belgium 🇧🇪 The post-CDK4/6 inhibitor landscape in HR+/HER2– advanced breast cancer represents one of the most pressing unmet needs in oncology. While CDK4/6 inhibitors combined with endocrine therapy have firmly established themselves as the frontline standard, disease progression on this backbone remains nearly universal, driven by heterogeneous resistance mechanisms including ESR1 mutations, PI3K/AKT/mTOR pathway alterations, and RB1 loss. This biological diversity highlights the limitations of one-size-fits-all approaches. Next-generation oral selective estrogen receptor degraders (SERDs)—such as elacestrant, camizestrant, and imlunestrant—are reshaping the field. These agents achieve more complete estrogen receptor degradation than fulvestrant, show activity in ESR1-mutant disease, and are being actively evaluated in combination strategies with CDK4/6 and targeted therapies. Together, they are helping shift the post-CDK4/6 setting toward a more dynamic, biomarker-informed treatment paradigm. This OncoAlert Horizons educational series was supported by an unrestricted educational grant from Roche. All content was independently developed and fully controlled by the faculty. OncoAlert Horizons faculty: @LoiSher @JavierCortesMD @BarbaraPistill2 @BianchiniGP @ElisaAgostinett Sybille Loibl Rupert Barsch Francois Clement Didard Cristina Saura Pinging our #BreastCancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @Onco_Cifu88

English
0
3
12
860
The Economist
The Economist@TheEconomist·
“I think  it’s time we need to bring this whole field into the medical realm.” On “The Weekend Intelligence”: why the science of breastfeeding is still in its infancy economist.com/podcasts/2026/…
English
4
2
13
21.3K
Sherene Loi, MD
Sherene Loi, MD@LoiSher·
#ESMOBreast26 Giredestrant with & w/o OFS -premenopausal WOO c/w AI+OFS Strong anti- proliferative effect of G w/o OFS esp in older premopausal women similar to AI+ OFS. Despite NS results these data provide support that G w/o OFS IS an option - further work to be done ✅ @elisabettasabet 👏@breastDoktor @etop_ibcsg
Sherene Loi, MD tweet media
English
1
9
15
1.8K
Sherene Loi, MD
Sherene Loi, MD@LoiSher·
#ESMObreast26 Mirinae study- 👏👏interesting signal for Atezo in PD-L1 pos RD post NAC for eTNBC (no NA Pembro). Immune cold tumors here. Underpowered but lesson is that these RD IO studies need to be powered for & enrol the immune HOT 🥵 group only @myESMO @OncoAlert
Sherene Loi, MD tweet mediaSherene Loi, MD tweet mediaSherene Loi, MD tweet media
English
2
10
20
2.2K
Sherene Loi, MD
Sherene Loi, MD@LoiSher·
➡️As a biomarker advocate, this decision needs commenting. #SERENA6 proves #camizestrant has strong drug activity in emerging ESR1m disease, stronger than approved SERDs post-progression. FDA accepts PFS without OS for other SERDs at radiographic progression; the higher bar here is apparently the earlier PFS start point. But the 9.2m control PFS does not mean "no need to act" it is a window where ESR1 subclones can be intercepted before broader and tougher to treat resistance biology beyond ESR1m emerges and dominates. Two separate questions: drug efficacy evidence (clearly established) vs strategy evidence (needs further study). Demanding a definitive strategy trial before approving a drug with this activity sets a precedent that, IMO, will harm precision oncology. Such a trial needs years more time, money, patients & impossible in a changing 2L landscape. @oncoalert @FDAOncology #bcsm
Harold J. Burstein, MD, PhD, FASCO@DrHBurstein

The @FDAOncology just posted materials for the ODAC on camizestrant in SERENA-6 trial. Key issue: PFS/PFS2. Should be a very interesting discussion. fda.gov/media/192156/d…

English
6
18
42
12.3K
financebully
financebully@financebully·
@LoiSher @drsarahsam @OncoAlert you’re mixing up serena-6 and serena-2. both different pt populations from veritac-2, but serena-2 is most comparable. still, it’s not just about the topline numbers, you have to look deeper. $arvn has best efficacy so far in true 2l post-cdk4/6 pts. combinability is the problem.
financebully tweet media
English
1
0
1
376
Sherene Loi, MD retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
What are the key issues that have emerged on the @NatureMedicine time-of-day IO paper? 1. The clinical trial protocol uploaded to Nature was v1 dated Jan 2, 2022; however, the protocol includes references published in 2024. This calls into question when the protocol was written and if/when it was amended. 2. The clinicaltrials.gov record is concerning and calls into question whether the study was actually randomized. a. In the first record 9/2022, although the study was noted as randomized, the inclusion/exclusion criteria read as though it was a retrospective study, e.g., “First-line patients received immunological monotherapy or immunological combined chemotherapy” as an inclusion criteria and  “Lack of clinical diagnosis and treatment information or loss of follow-up” as an exclusion criteria. b. In the first record, the primary endpoint, sample size, treatment and ECOG criteria do not match what was in the protocol dated Jan 2, 2022.  c. On 3/19/2024, the study was changed from randomized/interventional to an observational case-control study d. It was not until 3/30/2024 (2 months before end of randomization) that the study was changed to the design described in the manuscript. 3. The OS K-M curve presented at ASCO had errors – i.e., the censor marks do not match the at-risk table. This raises concerns about the integrity of statistical analyses. 4. The shape of the PFS does not match expectations. With a 6-week scan schedule, one would expect a stair-step drop every 6 weeks when patients have their scheduled imaging. Their PFS curve does not – it is smooth. Of note, in an observational study, a PFS curve generally does not have a staircase look because scans are not performed on a regular set schedule. 5. The 95% CI for the lower bound of the median OS in the manuscript is NE. This is not possible as the median was estimated. There are inconsistencies in the p-values in Table 1 (Baseline Characteristics) Credit to Daniel Brickman, Amanda Nottke and David Swank for creating this list — and to @houndcl for first identifying several of these issues.
Paolo Tarantino@PTarantinoMD

Impressive job of post-publication Twitter peer review on this paper! With the effect size appearing inexplicably massive, plus the many inconsistencies in study conduct and reporting, it’s safe to assume the “time-of-day IO” question still fully open. nature.com/articles/s4159…

English
11
65
206
119.5K
Sherene Loi, MD
Sherene Loi, MD@LoiSher·
👏👏👏 Must read from @S_LoboMartins in @NatRevClinOncol on ER+ early breast cancer in younger women. Key point: outcomes reflect an aggressive tumour genotype/phenotype that can overcome strong host immunity, combined with constant hormonal cycling that remodels the breast and immunity systemically ➡️we need treatments focussed for young biology @oncoalert #breastcancer #bcsm
Soraia Lobo-Martins@S_LoboMartins

Read our latest #review on tailoring targeted therapies for #younger women with #ER+ early #BreastCancer in @NatRevClinOncol, @SpringerNature. We discuss biology-driven treatment strategies beyond age alone. With Stephen Luen, Martine Piccart & @LoiSher 🔗doi.org/10.1038/s41571…

English
1
6
22
3.6K

Keşfet

@OncoAlert @ElisaAgostinett @NatRevImmunol @bk_esme @txi_ber @FoxChaseCancer @PeterMacCC @TheEconomist